219 related articles for article (PubMed ID: 25087756)
1. Active immunotherapy facilitates Aβ plaque removal following through microglial activation without obvious T cells infiltrating the CNS.
Sha S; Xing XN; Cao YP
J Neuroimmunol; 2014 Sep; 274(1-2):62-70. PubMed ID: 25087756
[TBL] [Abstract][Full Text] [Related]
2. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model.
Mouri A; Noda Y; Hara H; Mizoguchi H; Tabira T; Nabeshima T
FASEB J; 2007 Jul; 21(9):2135-48. PubMed ID: 17341681
[TBL] [Abstract][Full Text] [Related]
3. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
[TBL] [Abstract][Full Text] [Related]
4. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
5. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology.
Nemirovsky A; Shapiro J; Baron R; Kompaniets A; Monsonego A
J Neuroimmunol; 2012 Jun; 247(1-2):95-9. PubMed ID: 22498096
[TBL] [Abstract][Full Text] [Related]
6. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.
Wilcock DM; Munireddy SK; Rosenthal A; Ugen KE; Gordon MN; Morgan D
Neurobiol Dis; 2004 Feb; 15(1):11-20. PubMed ID: 14751766
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease.
Rosset MB; Lui G; Dansokho C; Chaigneau T; Dorothée G
J Neuroinflammation; 2015 May; 12():95. PubMed ID: 25982697
[TBL] [Abstract][Full Text] [Related]
9. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.
Bowers WJ; Mastrangelo MA; Stanley HA; Casey AE; Milo LJ; Federoff HJ
Neurobiol Aging; 2005 Apr; 26(4):393-407. PubMed ID: 15653168
[TBL] [Abstract][Full Text] [Related]
10. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
[TBL] [Abstract][Full Text] [Related]
11. 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice.
Zhang Y; Zou J; Yang J; Yao Z
Curr Alzheimer Res; 2015; 12(4):384-97. PubMed ID: 25817256
[TBL] [Abstract][Full Text] [Related]
12. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
[TBL] [Abstract][Full Text] [Related]
13. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
Kim HD; Tahara K; Maxwell JA; Lalonde R; Fukuiwa T; Fujihashi K; Van Kampen KR; Kong FK; Tang DC; Fukuchi K
J Gene Med; 2007 Feb; 9(2):88-98. PubMed ID: 17219449
[TBL] [Abstract][Full Text] [Related]
14. [Current trend of immunotherapy for Alzheimer's disease].
Matsumoto SE; Tabira T
Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
[TBL] [Abstract][Full Text] [Related]
15. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.
Dickstein DL; Biron KE; Ujiie M; Pfeifer CG; Jeffries AR; Jefferies WA
FASEB J; 2006 Mar; 20(3):426-33. PubMed ID: 16507760
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Res; 2017 Jun; 119():7-14. PubMed ID: 28111220
[TBL] [Abstract][Full Text] [Related]
17. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
Qu BX; Xiang Q; Li L; Johnston SA; Hynan LS; Rosenberg RN
J Neurol Sci; 2007 Sep; 260(1-2):204-13. PubMed ID: 17574274
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
Boche D; Denham N; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
[TBL] [Abstract][Full Text] [Related]
19. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.
Obregon D; Hou H; Bai Y; Nikolic WV; Mori T; Luo D; Zeng J; Ehrhart J; Fernandez F; Morgan D; Giunta B; Town T; Tan J
Neurobiol Dis; 2008 Feb; 29(2):336-53. PubMed ID: 18055209
[TBL] [Abstract][Full Text] [Related]
20. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
